Diaceutics (LON:DXRX) Issues Quarterly Earnings Results

Diaceutics (LON:DXRX - Get Free Report) issued its earnings results on Tuesday. The company reported GBX (2.02) (($0.03)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%.

Diaceutics Stock Down 0.8%

DXRX traded down GBX 1 ($0.01) during trading on Friday, hitting GBX 130 ($1.73). 266,928 shares of the company's stock were exchanged, compared to its average volume of 123,805. The business's 50 day moving average is GBX 120.30 and its two-hundred day moving average is GBX 127.14. The stock has a market cap of £109.71 million, a P/E ratio of -38.56 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. Diaceutics has a fifty-two week low of GBX 106 ($1.41) and a fifty-two week high of GBX 151 ($2.01).

Insider Activity

In other news, insider Peter Keeling sold 500,000 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of GBX 126 ($1.67), for a total value of £630,000 ($836,875.66). 34.30% of the stock is currently owned by corporate insiders.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.